Tioredoxin reductase ? a new target for molecular medical investigations

• Authors: P. Zagrodzki
• Languages of publication: PL

Abstracts

EN

Thioredoxin reductase (TrxR) is the first selenoenzyme containing selenocysteine in the active center and FAD as a second prosthetic group. TrxR catalyses the NADPH-dependent reduction of tioredoxin and of many other physiologically important substrates. TrxR exhibits many-fold increased activity in tumor cells and stimulates their proliferation as well the phenotype changes. Some gold compounds and a number of other clinically and experimentally used drugs have been shown to inhibit TrxR. The involvement of TrxR/Trx/NADPH system in broad spectrum of cellular processes renders it potential target for therapeutic approaches.

Keywords

EN

IMMUNOLOGICAL SYSTEM   SELENOENZYME   TIOREDOXINE REDUCTASE  

Discipline

• EXPERIMENTAL_BIOLOGY_&_MEDICINE: EXPERIMENTAL BIOLOGY & MEDICINE

• Publisher: Index Copernicus International; Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences
• Journal: Postępy Higieny i Medycyny Doświadczalnej
• Year: 2002
• Volume: 56
• Issue: 2
• Pages: 155-167
• Document Type: ARTICLE
• Publication order reference: P. Zagrodzki, Zaklad Bromatologii CM UJ, ul. Medyczna 9, 30-688 Krakow, Poland